Tags

Type your tag names separated by a space and hit enter

Clinical studies of sucralfate in reflux esophagitis. The European experience.
J Clin Gastroenterol. 1991; 13 Suppl 2:S16-20.JC

Abstract

Reflux esophagitis is encountered quite frequently in clinical practice. Symptoms can be mild, moderate, or severe and complications can occur, particularly if the disorder is untreated or undertreated. Treatment is aimed at relieving symptoms, healing lesions, and preventing complications. Various pharmacologic options are available for treatment, including antacids, alginate/antacid compounds, acid-reducing agents, prokinetic drugs, and agents that protect the mucosa. This article reviews a number of clinical studies evaluating sucralfate in the treatment of reflux esophagitis. Almost all of the investigations were conducted in Europe and encompassed open-label studies, placebo-controlled trials, and comparative studies. From the studies discussed, it can be concluded that sucralfate not only has a place in the treatment of peptic ulcer disease, but is also effective in treating reflux esophagitis. Sucralfate is comparable to H2-receptor antagonists in symptom improvement and healing rates. In addition, the studies reviewed have shown sucralfate to be safe and well tolerated.

Authors+Show Affiliations

Department of Gastroenterology, Free University of Amsterdam, The Netherlands.

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Review

Language

eng

PubMed ID

1885899

Citation

Hameeteman, W. "Clinical Studies of Sucralfate in Reflux Esophagitis. the European Experience." Journal of Clinical Gastroenterology, vol. 13 Suppl 2, 1991, pp. S16-20.
Hameeteman W. Clinical studies of sucralfate in reflux esophagitis. The European experience. J Clin Gastroenterol. 1991;13 Suppl 2:S16-20.
Hameeteman, W. (1991). Clinical studies of sucralfate in reflux esophagitis. The European experience. Journal of Clinical Gastroenterology, 13 Suppl 2, S16-20.
Hameeteman W. Clinical Studies of Sucralfate in Reflux Esophagitis. the European Experience. J Clin Gastroenterol. 1991;13 Suppl 2:S16-20. PubMed PMID: 1885899.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical studies of sucralfate in reflux esophagitis. The European experience. A1 - Hameeteman,W, PY - 1991/1/1/pubmed PY - 1991/1/1/medline PY - 1991/1/1/entrez SP - S16 EP - 20 JF - Journal of clinical gastroenterology JO - J. Clin. Gastroenterol. VL - 13 Suppl 2 N2 - Reflux esophagitis is encountered quite frequently in clinical practice. Symptoms can be mild, moderate, or severe and complications can occur, particularly if the disorder is untreated or undertreated. Treatment is aimed at relieving symptoms, healing lesions, and preventing complications. Various pharmacologic options are available for treatment, including antacids, alginate/antacid compounds, acid-reducing agents, prokinetic drugs, and agents that protect the mucosa. This article reviews a number of clinical studies evaluating sucralfate in the treatment of reflux esophagitis. Almost all of the investigations were conducted in Europe and encompassed open-label studies, placebo-controlled trials, and comparative studies. From the studies discussed, it can be concluded that sucralfate not only has a place in the treatment of peptic ulcer disease, but is also effective in treating reflux esophagitis. Sucralfate is comparable to H2-receptor antagonists in symptom improvement and healing rates. In addition, the studies reviewed have shown sucralfate to be safe and well tolerated. SN - 0192-0790 UR - https://www.unboundmedicine.com/medline/citation/1885899/Clinical_studies_of_sucralfate_in_reflux_esophagitis__The_European_experience_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=1885899.ui DB - PRIME DP - Unbound Medicine ER -